Success Metrics

Active Trials
2(40%)

Phase Distribution

Ph phase_3
2
40%
Ph phase_2
3
60%

Phase Distribution

0

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Not yet recruiting3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 23 (60.0%)
Phase 32 (40.0%)

Trials by Status

not_yet_recruiting360%
recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_3

Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy

NCT07528716
not_yet_recruitingphase_3

An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC

NCT07669610
not_yet_recruitingphase_2

SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

NCT07307287
not_yet_recruitingphase_2

SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression

NCT07047443
recruitingphase_2

A Study of SHR-A1811 in Subjects With Gynaecologic Oncology

NCT05896020

Clinical Trials (5)

Showing 5 of 5 trials
NCT07528716Phase 3

Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy

Recruiting
NCT07669610Phase 3

An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC

Not Yet Recruiting
NCT07307287Phase 2

SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

Not Yet Recruiting
NCT07047443Phase 2

SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression

Not Yet Recruiting
NCT05896020Phase 2

A Study of SHR-A1811 in Subjects With Gynaecologic Oncology

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5